SAB Biotherapeutics (SABS) Cash from Operations (2020 - 2026)
SAB Biotherapeutics' (SABS) quarterly Cash from Operations came in at 14271130.0 in Q1 2026, down 83.03% YoY from 84088839.33 in Q1 2025, and up 14.93% on a QoQ basis from 16776327.0 in Q4 2025.
Powered by 
Analysis
SAB Biotherapeutics (SABS) Cash from Operations (2020 - 2026) Analysis & Trends
SAB Biotherapeutics (SABS) has 7 years of Cash from Operations data on file, last reported at 14271130.0 in Q1 2026.
- Quarterly Cash from Operations fell 83.03% year-over-year to 14271130.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 51249024.0 (down 63.53% YoY) and the FY2025 annual result came in at 44775111.0, down 30.57% from the prior year.
- Cash from Operations improved to 14271130.0 in Q1 2026, from 16776327.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 1555024.0 in Q4 2022 to a low of 16776327.0 in Q4 2025.
- A 5-year average of 8348068.59 and a median of 7797217.0 in 2025 frame the typical range for Cash from Operations.
- The widest YoY moves for Cash from Operations: up 83.16% in 2023, down 764.73% in 2023.
- Tracing SABS's Cash from Operations over 5 years: stood at 1555024.0 in 2022, then plunged by 764.73% to 13446717.0 in 2023, then increased by 29.11% to 9532188.0 in 2024, then slumped by 76.0% to 16776327.0 in 2025, then increased by 14.93% to 14271130.0 in 2026.
- The last three Cash from Operations figures came in at 14271130.0 (Q1 2026), 16776327.0 (Q4 2025), and 13050023.0 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -526.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -387.32 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 462.82 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 326.72 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 728.46 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -88.83 Mn |
| 10 | SAB Biotherapeutics | 296.68 Mn | 296.68 Mn | - | -9.84 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -9.84 Mn |
| Mar 31, 2026 | -14.27 Mn |
| Dec 31, 2025 | -16.78 Mn |
| Sep 30, 2025 | -13.05 Mn |
| Jun 30, 2025 | -7.15 Mn |
| Mar 31, 2025 | -7.80 Mn |
| Dec 31, 2024 | -9.53 Mn |
| Sep 30, 2024 | -6.29 Mn |
| Jun 30, 2024 | -7.72 Mn |
| Mar 31, 2024 | -10.75 Mn |
| Dec 31, 2023 | -13.45 Mn |
| Sep 30, 2023 | -5.17 Mn |
| Jun 30, 2023 | -4.90 Mn |
| Mar 31, 2023 | -1.61 Mn |
| Dec 31, 2022 | -1.56 Mn |
| Sep 30, 2022 | -7.92 Mn |
| Jun 30, 2022 | -4.45 Mn |
| Mar 31, 2022 | -9.54 Mn |
| Dec 31, 2021 | -4.88 Mn |
| Sep 30, 2021 | 3.80 Mn |